Skip to main content
OTCMKTS:SPHRY

Starpharma Competitors

$12.39
-0.51 (-3.95 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.29
$12.67
50-Day Range
$12.90
$16.30
52-Week Range
$6.20
$19.87
Volume7,718 shs
Average Volume3,472 shs
Market Capitalization$503.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86

Competitors

Starpharma (OTCMKTS:SPHRY) Vs. PGEN, NRC, AVXL, LUNA, CBWTF, and PIRS

Should you be buying SPHRY stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to Starpharma, including Precigen (PGEN), National Research (NRC), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Auxly Cannabis Group (CBWTF), and Pieris Pharmaceuticals (PIRS).

Precigen (NASDAQ:PGEN) and Starpharma (OTCMKTS:SPHRY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Precigen and Starpharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precigen$90.72 million15.74$-322,320,000.00($0.88)-7.86
Starpharma$4.40 million114.35$-9,860,000.00N/AN/A

Starpharma has lower revenue, but higher earnings than Precigen.

Institutional & Insider Ownership

66.6% of Precigen shares are held by institutional investors. 50.7% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Precigen has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Starpharma has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Profitability

This table compares Precigen and Starpharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precigen-295.57%-150.85%-25.85%
StarpharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Precigen and Starpharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precigen00503.00
Starpharma0000N/A

Precigen currently has a consensus target price of $12.80, indicating a potential upside of 84.97%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Starpharma.

Summary

Precigen beats Starpharma on 6 of the 11 factors compared between the two stocks.

National Research (NASDAQ:NRC) and Starpharma (OTCMKTS:SPHRY) are both small-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares National Research and Starpharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Research$127.98 million9.75$32.41 millionN/AN/A
Starpharma$4.40 million114.35$-9,860,000.00N/AN/A

National Research has higher revenue and earnings than Starpharma.

Institutional & Insider Ownership

41.7% of National Research shares are held by institutional investors. 4.2% of National Research shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

National Research has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Starpharma has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Profitability

This table compares National Research and Starpharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
National Research28.79%87.53%32.09%
StarpharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for National Research and Starpharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
National Research0000N/A
Starpharma0000N/A

Summary

National Research beats Starpharma on 7 of the 9 factors compared between the two stocks.

Anavex Life Sciences (NASDAQ:AVXL) and Starpharma (OTCMKTS:SPHRY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Anavex Life Sciences and Starpharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anavex Life Sciences00503.00
Starpharma0000N/A

Anavex Life Sciences currently has a consensus target price of $17.60, indicating a potential upside of 58.84%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Starpharma.

Earnings and Valuation

This table compares Anavex Life Sciences and Starpharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A$-26,280,000.00($0.45)-24.62
Starpharma$4.40 million114.35$-9,860,000.00N/AN/A

Starpharma has higher revenue and earnings than Anavex Life Sciences.

Volatility and Risk

Anavex Life Sciences has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Starpharma has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Institutional & Insider Ownership

18.9% of Anavex Life Sciences shares are held by institutional investors. 12.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Anavex Life Sciences and Starpharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anavex Life SciencesN/A-102.39%-81.73%
StarpharmaN/AN/AN/A

Summary

Starpharma beats Anavex Life Sciences on 5 of the 9 factors compared between the two stocks.

Starpharma (OTCMKTS:SPHRY) and Luna Innovations (NASDAQ:LUNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Starpharma and Luna Innovations, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Starpharma0000N/A
Luna Innovations00103.00

Luna Innovations has a consensus target price of $14.50, indicating a potential upside of 24.25%. Given Luna Innovations' higher probable upside, analysts plainly believe Luna Innovations is more favorable than Starpharma.

Valuation and Earnings

This table compares Starpharma and Luna Innovations' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Starpharma$4.40 million114.35$-9,860,000.00N/AN/A
Luna Innovations$70.52 million5.20$5.34 million$0.1768.65

Luna Innovations has higher revenue and earnings than Starpharma.

Volatility and Risk

Starpharma has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Institutional and Insider Ownership

42.4% of Luna Innovations shares are held by institutional investors. 11.2% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Starpharma and Luna Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
StarpharmaN/AN/AN/A
Luna Innovations7.21%10.72%8.32%

Summary

Luna Innovations beats Starpharma on 9 of the 11 factors compared between the two stocks.

Starpharma (OTCMKTS:SPHRY) and Auxly Cannabis Group (OTCMKTS:CBWTF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares Starpharma and Auxly Cannabis Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
StarpharmaN/AN/AN/A
Auxly Cannabis Group-332.96%-47.37%-28.34%

Institutional and Insider Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Starpharma and Auxly Cannabis Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Starpharma0000N/A
Auxly Cannabis Group00303.00

Auxly Cannabis Group has a consensus target price of $0.40, indicating a potential upside of 47.33%. Given Auxly Cannabis Group's higher probable upside, analysts plainly believe Auxly Cannabis Group is more favorable than Starpharma.

Valuation and Earnings

This table compares Starpharma and Auxly Cannabis Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Starpharma$4.40 million114.35$-9,860,000.00N/AN/A
Auxly Cannabis Group$6.29 million32.36$-77,300,000.00N/AN/A

Starpharma has higher earnings, but lower revenue than Auxly Cannabis Group.

Volatility and Risk

Starpharma has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Auxly Cannabis Group has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Summary

Starpharma beats Auxly Cannabis Group on 6 of the 10 factors compared between the two stocks.

Starpharma (OTCMKTS:SPHRY) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Starpharma and Pieris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
StarpharmaN/AN/AN/A
Pieris Pharmaceuticals-59.11%-55.20%-21.21%

Institutional & Insider Ownership

57.5% of Pieris Pharmaceuticals shares are owned by institutional investors. 6.6% of Pieris Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Starpharma and Pieris Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Starpharma0000N/A
Pieris Pharmaceuticals00203.00

Pieris Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 378.72%. Given Pieris Pharmaceuticals' higher probable upside, analysts clearly believe Pieris Pharmaceuticals is more favorable than Starpharma.

Valuation & Earnings

This table compares Starpharma and Pieris Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Starpharma$4.40 million114.35$-9,860,000.00N/AN/A
Pieris Pharmaceuticals$46.28 million2.57$-25,470,000.00($0.56)-3.36

Starpharma has higher earnings, but lower revenue than Pieris Pharmaceuticals.

Risk & Volatility

Starpharma has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Summary

Starpharma beats Pieris Pharmaceuticals on 6 of the 11 factors compared between the two stocks.


Starpharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Precigen logo
PGEN
Precigen
1.7$6.92-7.5%$1.43 billion$90.72 million-3.68Analyst Report
Insider Selling
Gap Down
National Research logo
NRC
National Research
0.8$49.06-0.5%$1.25 billion$127.98 million33.37News Coverage
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.3$11.08-8.3%$775.94 millionN/A-24.62Earnings Announcement
News Coverage
Gap Down
Luna Innovations logo
LUNA
Luna Innovations
1.3$11.67-3.8%$366.42 million$70.52 million64.83Upcoming Earnings
Gap Down
Auxly Cannabis Group logo
CBWTF
Auxly Cannabis Group
1.4$0.27-3.7%$203.55 million$6.29 million-1.94News Coverage
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$1.88-0.5%$119.01 million$46.28 million-3.55Upcoming Earnings
Bioqual logo
BIOQ
Bioqual
0.9$92.00-0.0%$82.43 million$46.36 million17.56
Cleveland BioLabs logo
CBLI
Cleveland BioLabs
0.6$4.66-3.0%$72.09 million$1.11 million0.00Upcoming Earnings
Gap Down
Eloxx Pharmaceuticals logo
ELOX
Eloxx Pharmaceuticals
1.2$1.35-25.9%$64.61 millionN/A-1.35Earnings Announcement
High Trading Volume
News Coverage
ProMIS Neurosciences logo
ARFXF
ProMIS Neurosciences
0.0$0.14-2.2%$44.15 millionN/A-7.20
NNVC
NanoViricides
0.4$3.42-9.4%$36.52 millionN/A0.00Gap Down
AIkido Pharma logo
AIKI
AIkido Pharma
1.0$0.90-5.5%$31.60 million$10,000.000.00Gap Down
Tenax Therapeutics logo
TENX
Tenax Therapeutics
1.4$2.06-2.4%$30.84 millionN/A-1.70Upcoming Earnings
Gap Down
Inhibitor Therapeutics logo
INTI
Inhibitor Therapeutics
0.0$0.07-0.0%$27.36 millionN/A0.00Upcoming Earnings
Gap Up
HPPI
HedgePath Pharmaceuticals
0.4$0.07-0.0%$26.97 millionN/A0.00Gap Up
U.S. Stem Cell logo
USRM
U.S. Stem Cell
0.6$0.02-0.0%$10.44 million$6.70 million0.00
Vitality Biopharma logo
VBIO
Vitality Biopharma
0.5$0.20-15.0%$10.11 million$260,000.000.00Gap Down
Protalex logo
PRTX
Protalex
0.9$0.01-0.0%$615,000.00N/A0.00
DNAG
DNAPrint Genomics
0.0$0.00-0.0%$518,000.00N/A0.00
ALGXY
Affinity Energy and Health
0.4$0.00-0.0%$0.00$2.05 million0.00
DGEN
Deltagen
0.2$0.00-0.0%$0.00N/A0.00
RPBC
Redpoint Bio
0.5$0.00-0.0%$0.00N/A0.00
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.